← Back to Search

Intravenous Anesthesia

Burst Suppression Therapy for Seizures after Cardiac Arrest (RESTORE Trial)

Phase 2
Recruiting
Led By Edilberto Amorim, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Non-traumatic, out-of-hospital cardiac arrest
Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous EEG monitoring within 7 days from ROSC
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24-48 hours
Awards & highlights

RESTORE Trial Summary

This trial is studying if an electrical brain stimulation therapy is safe & helpful for people with life-threatening seizures after a heart attack.

Who is the study for?
This trial is for adults over 18 who've had a non-traumatic, out-of-hospital cardiac arrest and are now in a coma with refractory status epilepticus confirmed by EEG. They must have regained circulation within 45 minutes and be admitted to the ICU. It's not for those with acute brain bleeding or stroke, pregnant women, or prisoners.Check my eligibility
What is being tested?
The RESTORE trial is comparing two types of intravenous anesthesia based on EEG targets: one aiming for burst suppression (reducing brain activity) and the other for seizure suppression (stopping seizures), to see which is safer and more feasible after cardiac arrest.See study design
What are the potential side effects?
Potential side effects may include typical risks associated with general anesthesia such as respiratory depression, low blood pressure, allergic reactions, and potential impact on brain function due to changes in electrical activity monitored by EEG.

RESTORE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had a sudden heart stoppage outside of a hospital without injury.
Select...
I was diagnosed with a severe seizure condition after a heart attack, confirmed by EEG.
Select...
I am 18 years old or older.
Select...
I have been admitted to the intensive care unit.
Select...
I was unable to follow commands upon hospital admission.

RESTORE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24-48 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24-48 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Post-cardiac arrest refractory status epilepticus control
Secondary outcome measures
Neurological Function 180 days (mRS: modified Ranking Scale)
Neurological Function 90 days (CPC: Cerebral Performance Category)
Neurological Function 90 days (mRS: modified Ranking Scale)
+5 more

RESTORE Trial Design

2Treatment groups
Experimental Treatment
Group I: Seizure Suppression EEG TargetExperimental Treatment1 Intervention
Anesthetic will be titrated to achieve seizure suppression on continuous EEG for 24 hours.
Group II: Burst Suppression EEG TargetExperimental Treatment1 Intervention
Anesthetic will be titrated to achieve burst suppression on continuous EEG (50-99% attenuation/suppression) for 24 hours.

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,507 Previous Clinical Trials
15,238,545 Total Patients Enrolled
7 Trials studying Seizures
1,336 Patients Enrolled for Seizures
The ZOLL FoundationUNKNOWN
Edilberto Amorim, MDPrincipal InvestigatorAssistant Professor of Neurology

Media Library

Burst Suppression EEG Target Intravenous Anesthesia (Intravenous Anesthesia) Clinical Trial Eligibility Overview. Trial Name: NCT05851391 — Phase 2
Seizures Research Study Groups: Burst Suppression EEG Target, Seizure Suppression EEG Target
Seizures Clinical Trial 2023: Burst Suppression EEG Target Intravenous Anesthesia Highlights & Side Effects. Trial Name: NCT05851391 — Phase 2
Burst Suppression EEG Target Intravenous Anesthesia (Intravenous Anesthesia) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05851391 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this particular therapy been granted approval by the Food and Drug Administration?

"Due to the absence of efficacy data, this treatment was assigned a safety rating of 2. However, there is some existing evidence suggesting that it is safe for use in clinical trials."

Answered by AI

Is there still capacity for participants in this research project?

"As indicated in the clinicaltrials.gov records, this particular trial is no longer searching for volunteers to partake in it; its inception was on May 1st 2023 and it's record has not been adjusted since then. Nevertheless, there exist 841 alternative medical studies that are currently accepting patients."

Answered by AI

Who else is applying?

What site did they apply to?
Zuckerberg San Francisco General Hospital
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

I just finished a month and half long DOC program which did not result in me emerging. I am looking at alternatives.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

How long before I hear back from you regarding this trial ?
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
2023. "buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05851391.
All > Cardiac Arrest
~14 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top